Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Net Asset Quality Index
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Net Asset Quality Index of 83.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.53 Billion minus total liabilities of CN¥893.57 Million yields net assets of CN¥4.64 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Tianjin Lisheng Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Tianjin Lisheng Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2006–2025)
This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 20 annual periods from 2006 to 2025. As of March 2026, the index stands at 83.9%, representing net assets of CN¥4.64 Billion against total assets of CN¥5.53 Billion CNY. For live market cap and overall valuation, see Tianjin Lisheng Pharmaceutical Co Ltd stock valuation.
Annual Net Asset Quality Index for Tianjin Lisheng Pharmaceutical Co Ltd (2006–2025)
The table below presents the year-by-year Net Asset Quality Index for Tianjin Lisheng Pharmaceutical Co Ltd from 2006 to 2025, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check asset allocation strategy of Tianjin Lisheng Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 84.0% | CN¥4.69 Billion | CN¥5.58 Billion | CN¥890.89 Million | ▲ +1.1 pp |
| 2024 | 83.0% | CN¥4.80 Billion | CN¥5.79 Billion | CN¥985.54 Million | ▼ -1.9 pp |
| 2023 | 84.8% | CN¥4.90 Billion | CN¥5.78 Billion | CN¥877.17 Million | ▲ +2.6 pp |
| 2022 | 82.2% | CN¥4.35 Billion | CN¥5.29 Billion | CN¥941.66 Million | ▼ -2.8 pp |
| 2021 | 85.0% | CN¥4.41 Billion | CN¥5.19 Billion | CN¥780.42 Million | ▼ -0.7 pp |
| 2020 | 85.7% | CN¥4.30 Billion | CN¥5.02 Billion | CN¥720.09 Million | ▲ +1.9 pp |
| 2019 | 83.8% | CN¥4.42 Billion | CN¥5.27 Billion | CN¥855.85 Million | ▲ +1.8 pp |
| 2018 | 82.0% | CN¥3.21 Billion | CN¥3.92 Billion | CN¥704.85 Million | ▼ -1.6 pp |
| 2017 | 83.6% | CN¥3.08 Billion | CN¥3.68 Billion | CN¥602.32 Million | ▼ -2.9 pp |
| 2016 | 86.5% | CN¥3.02 Billion | CN¥3.49 Billion | CN¥470.60 Million | ▼ -0.6 pp |
| 2015 | 87.1% | CN¥2.97 Billion | CN¥3.41 Billion | CN¥439.50 Million | ▼ -2.5 pp |
| 2014 | 89.6% | CN¥2.91 Billion | CN¥3.25 Billion | CN¥337.89 Million | ▼ -1.1 pp |
| 2013 | 90.7% | CN¥2.92 Billion | CN¥3.22 Billion | CN¥298.20 Million | ▼ -4.2 pp |
| 2012 | 95.0% | CN¥2.79 Billion | CN¥2.93 Billion | CN¥148.13 Million | ▼ -2.8 pp |
| 2011 | 97.8% | CN¥2.80 Billion | CN¥2.86 Billion | CN¥64.07 Million | ▲ +0.6 pp |
| 2010 | 97.2% | CN¥2.65 Billion | CN¥2.73 Billion | CN¥77.12 Million | ▲ +43.8 pp |
| 2009 | 53.4% | CN¥470.87 Million | CN¥882.13 Million | CN¥411.26 Million | ▼ -10.3 pp |
| 2008 | 63.7% | CN¥474.77 Million | CN¥745.35 Million | CN¥270.58 Million | ▲ +14.2 pp |
| 2007 | 49.4% | CN¥432.23 Million | CN¥874.11 Million | CN¥441.87 Million | ▼ -2.5 pp |
| 2006 | 51.9% | CN¥448.45 Million | CN¥863.49 Million | CN¥415.03 Million | — |